EZH2 and melanoma: Additionally, T cell accumulation in the tumor during anti-CTLA-4 or IL-2 immunotherapy leads to an increase in EZH2 expression in melanoma cells, which further decreases their immunogenicity and antigen presentation, thus contributing to intrinsic resistance to these immunotherapies [87].